

2026 Kaohsiung International Cancer Symposium

Breast Cancer Session

3月21日(星期六) Saturday, 21 March

Time	Topic	Speaker	Moderator
07:50	Registration		
08:20-08:30	Opening Remarks		
08:30-09:00	Decoding the Metastatic Cascade: From Molecular Mechanisms to Therapeutic Vulnerabilities	Mei-Ren Pan 潘美仁	Ming-Feng Hou 侯明鋒
09:00-09:30	Homologous Repair Deficiency in Cellular Senescence and Breast Cancer Progression	Shyng-Shiou Yuan 袁行修	King-Jen Chang 張金堅
09:30-10:00	Practical Insights on Using TS-1 as Adjuvant Therapy in HR+/HER2- Early Breast Cancer: Cases, Tolerability, and Results	Li-Kun Ko 高理鈞	Shin-Cheh Chen 陳訓徹
10:00-10:30	Rethinking 1L AI Treatment in HR+/HER2- Breast Cancer: When Resistance Begins Earlier Than We Think	Shih-Yu Huang 黃詩喻	Jyh-Cherng Yu 俞志誠
10:30-10:50	Coffee Break		
10:50-11:20	Protecting Bone Integrity in Breast Cancer: Xgeva new formulation with Pre-Filled Syringe	Yi-Ching Huang 黃怡菁	Ling-Ming Tseng 曾令民
11:20-11:50	Unlocking the potential of ADC: Transforming HR+ metastatic breast cancer outcome after CDK4/6i across HER2 expression Spectrum	Chin-Yao Lin 林金瑤	Dar-Ren Chen 陳達人
11:50-12:20	Targeting the PIK3CA/AKT/PTEN Pathway: Rewriting Endocrine Therapy Continuum in HR+/HER2- mBC	Cheng-Wei Chou 周政緯	Shyr-Ming Sheen-Chen 沈陳石銘
12:20-13:20	Lunch		
13:20-14:00	Redefine the risk of recurrence in HR+ Her 2- breast cancer	Hsu-Huan Chou 周旭桓	Shou-Tung Chen 陳守棟
14:00-14:30	Emerging Strategies for First-Line Treatment of Endocrine Resistance HR+/Her2- mBC with PIK3CA mutation	An-Chieh Feng 馮安捷	Ming-Yang Wang 王明暘
14:30-15:00	Personalized Treatment Approaches in Metastatic Breast Cancer: Integrating TKIs into Clinical Practice	Chien-Ting Liu 劉建廷	Yen-Shen Lu 盧彥伸
15:00-15:30	Unveiling the TROP2 Story: The Clinical Benefit of Sacituzumab Govitecan in HER2-Metastatic Breast Cancer	Chi-Feng Chung 鍾奇峰	Tsui-Fen Cheng 鄭翠芬

Coffee Break			
15:30-15:50			
15:50-16:20	Early TNBC: Evidence, Experience, and Evolving Practice	Chih-Hao Huang 黃至豪	Tsu-Yi Chao 趙祖怡
16:20-16:50	First-Line to Beyond: Sequencing Strategies in mTNBC and Upcoming Options	Chan-Keng Yang 楊展庚	Hsien-Tang Yeh 葉顯堂
16:50-17:20	Advancing the SOC with T-DXd in HER2-positive mBC through real world experience	Ming-Han Yang 楊明翰	Chung-Liang Li 李忠良
17:20-18:00	Extending survival in HR+/HER2- early breast cancer: evolving strategies in adjuvant therapy	Po-Hsiang Huang 黃柏翔	Guo-Shiou Liao 廖國秀

Day2

3月22日(星期日) Sunday, 22 March

Time	Topic	Speaker	Moderator
08:30-09:00	Estrogen dependency of breast cancer, what we have learned so far from bench to bed	Shigehira Saji 佐治重衡	Takashi Ishikawa 石川孝
09:00-09:30	Randomized controlled trial of breast cancer screening by mammography with or without ultrasonography for women aged 40-49 : J-START Study	Takanori Ishida 石田孝宣	Chen-Hsiang Chang 張振祥
09:30-10:00	Current issues in Breast surgery in Japan	Shinji Ohno 大野真司	Chiun-Sheng Huang 黃俊升
10:00-10:30	Artificial Intelligence in Breast Cancer Care: Clinical Implementation, and Future Perspectives	Tetsu Hayashida 林田哲	Wen-Hung Kuo 郭文宏
10:30-10:50	Coffee Break		
10:50-11:20	Dialogue of Ribonucleases and Receptor Tyrosine Kinases and Immune Therapy	Mien-Chie Hung 洪明奇	Hui-Hua Hsiao 蕭惠樺
11:20-11:50	Breaking the Ceiling: Strategies to Reduce Recurrence in HER2+ Early Breast Cancer	Kuo-Ting Lee 李國鼎	Chao-Ming Hung 洪朝明
11:50-12:20	Genetic testing for breast cancer in the era of precision medicine	Chi-Cheng Huang 黃其晟	Fang-Ming Chen 陳芳銘
12:20-12:30	Closing	Fang-Ming Chen 陳芳銘	